•  
  •  
 

Article Type

Review

Abstract

The aim of this study was to study the relationship between serum level of soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) and the disease activity in patients with systemic lupus erythematosus (SLE) and also to compare sTRAIL levels between patients with lupus and patients with rheumatoid arthritis as well as healthy volunteers. A search was performed in Medline databases (PubMed, Medscape, Science Direct, and EMF-Portal) and all materials available in the Internet from 2000 to 2017. The initial search presented 18 articles of which eight met the inclusion criteria. These articles studied the relation between sTRAIL and the disease activity in patients with SLE. If the studies did not fulfill the inclusion criteria, they were excluded. Study quality assessment included whether ethical approval was gained, eligibility criteria specified, appropriate controls included, adequate information provided, and assessment measures defined. Comparisons were made by structured review with the results tabulated. In total, eight potentially relevant publications were included, and all were human studies. The studies had demonstrated elevated serum concentrations of sTRAIL in patients with SLE and their association with disease activity, which suggest an important role for TRAIL in the pathogenesis of SLE. Serum level of sTRAIL was significantly higher among patients with active SLE as compared with those of other groups and positively correlated with disease activity.

Download

Share

COinS